MUC16 and ovarian cancer: However, there was no sufficient evidence to suggest that the serial testing with MIA2G and IOTA-LR2 was statistically better than the seral testing with CA-125 and IOTA-LR2 in diagnosing early-stage ovarian cancer (p = 0.12).